Phil Darcy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne to advance its CAR-T programs utilising the OmniCAR platform. The new program builds on the company’s existing research agreement with Peter Mac focusing on cell therapy enhancement programs. The new agreement expands this relationship to include the development of the OmniCAR platform. The company said it is developing three OmniCAR programs internally, including next-generation CAR-T therapies for acute myeloid leukaemia (AML), Her2+ solid tumours and glioblastoma multiforme (GB...

Prescient Therapeutics signs CAR-T agreement with Peter Mac Cancer Centre The new CAR-T agreement for the OmniCAR platform adds to Prescient’s existing and related research program with Peter Mac into Cell Therapy Enhancements. OmniCAR seeks to make CAR-T more controllable and adaptable. Prescient Therapeutics Ltd (ASX:PTX) has signed an agreement related to advancing a new research program with world-renowned Peter MacCallum Cancer Centre to advance its next-generation CAR-T program utilising the OmniCAR platform. Prescient has an existing research agreement with Peter Mac focu...